PMID- 29445301
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220316
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 10
DP  - 2018
TI  - Comparative effectiveness of early-line nab-paclitaxel vs. paclitaxel in patients 
      with metastatic breast cancer: a US community-based real-world analysis.
PG  - 249-256
LID - 10.2147/CMAR.S150960 [doi]
AB  - BACKGROUND: Real-world analyses of treatments for patients with metastatic breast 
      cancer are limited. We evaluated the comparative effectiveness of nab-paclitaxel 
      vs. paclitaxel in patients with metastatic breast cancer using data from an 
      electronic medical record database from community practices across the USA. 
      METHODS: We performed a retrospective cohort study using fully de-identified data 
      from an independent US electronic medical record platform of patients with 
      metastatic breast cancer initiating single-agent nab-paclitaxel or paclitaxel as 
      a first- or second-line treatment from December 1, 2010 to October 6, 2014. The 
      clinical efficacy objectives were time to treatment discontinuation (TTD) and 
      time to next treatment (TTNT). Subgroup analyses were performed in patients with 
      2 types of metastatic breast cancer as follows: 1) hormone receptor-positive and 
      human epidermal growth factor receptor 2 negative, and 2) triple-negative 
      disease. RESULTS: This analysis included 925 patients. Patients receiving 
      nab-paclitaxel vs. paclitaxel had significantly longer TTD (median 4.2 vs. 2.8 
      months, P<0.0001) and TTNT (median 6.0 vs. 4.2 months, P<0.0001); similar 
      outcomes were observed for patients with hormone receptor-positive/human 
      epidermal growth factor receptor 2 negative disease. Compared with paclitaxel, 
      nab-paclitaxel was associated with significantly longer TTD in patients with 
      triple-negative disease. nab-Paclitaxel was associated with significantly less 
      all-grade neuropathy, anemia, pain, and diarrhea than paclitaxel. Antiemetic and 
      antihistamine use were significantly less frequent with nab-paclitaxel vs. 
      paclitaxel, whereas use of granulocyte colony-stimulating factor, hydrating 
      agents, and bone-directed therapy to decrease skeletal-related events were more 
      frequent. CONCLUSION: nab-Paclitaxel demonstrated improved clinical effectiveness 
      compared with paclitaxel when examining TTD and TTNT in patients with metastatic 
      breast cancer in a real-world setting.
FAU - Mahtani, Reshma L
AU  - Mahtani RL
AD  - Division of Hematology/Oncology, University of Miami, Miami, FL.
FAU - Parisi, Monika
AU  - Parisi M
AD  - Health Economics and Outcomes Research, Celgene Corporation, Summit, NJ.
FAU - Gluck, Stefan
AU  - Gluck S
AD  - Global Medical Affairs, Celgene Corporation, Summit, NJ.
FAU - Ni, Quanhong
AU  - Ni Q
AD  - Health Economics and Outcomes Research, Celgene Corporation, Summit, NJ.
FAU - Park, Siyeon
AU  - Park S
AD  - School of Pharmacy, The Ohio State University, Columbus, OH.
FAU - Pelletier, Corey
AU  - Pelletier C
AD  - Health Economics and Outcomes Research, Celgene Corporation, Summit, NJ.
FAU - Faria, Claudio
AU  - Faria C
AD  - Health Economics and Outcomes Research, Celgene Corporation, Summit, NJ.
FAU - Braiteh, Fadi
AU  - Braiteh F
AD  - Department of Hematology/Oncology, University of Nevada School of Medicine, Las 
      Vegas, NV.
AD  - Department of Hematology/Oncology, Comprehensive Cancer Centers of Nevada, Las 
      Vegas, NV, USA.
LA  - eng
PT  - Journal Article
DEP - 20180208
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC5808700
OTO - NOTNLM
OT  - hormone receptor positive
OT  - metastatic breast cancer
OT  - nab-paclitaxel
OT  - paclitaxel
OT  - triple negative
COIS- Disclosure RLM served on advisory boards for Genentech, Amgen, Sandoz, Celgene, 
      and Pfizer, received research support from Genentech, and served as a consultant 
      for Celgene and Pfizer. MP, SG, QN, CP, and CF are all employees of Celgene 
      Corporation. FB is a speaker and consultant for Celgene Corporation. The authors 
      report no other conflicts of interest in this work.
EDAT- 2018/02/16 06:00
MHDA- 2018/02/16 06:01
PMCR- 2018/02/08
CRDT- 2018/02/16 06:00
PHST- 2018/02/16 06:00 [entrez]
PHST- 2018/02/16 06:00 [pubmed]
PHST- 2018/02/16 06:01 [medline]
PHST- 2018/02/08 00:00 [pmc-release]
AID - cmar-10-249 [pii]
AID - 10.2147/CMAR.S150960 [doi]
PST - epublish
SO  - Cancer Manag Res. 2018 Feb 8;10:249-256. doi: 10.2147/CMAR.S150960. eCollection 
      2018.